Gene/Cell Therapies: Still Just A ‘Science Project’?
This article was originally published in The Pink Sheet Daily
Executive Summary
While an increasing number of South Korean biotech firms are looking to advance into overseas gene and cell therapy markets as part of the government's plan to develop these areas as a new growth engine, a U.S. regulatory expert has cautioned it is risky for bioventures to focus only on the gene and cell sectors while they still face major regulatory and commercialization hurdles.
You may also be interested in...
Gene Therapy’s Roller Coaster Ride
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.